Clinical trials: Corneal Defect
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Persistent Corneal Epithelial Defect
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
The objective of this study is to evaluate the safety and effectiveness of topical KIO-201 in patients with persistent corneal epithelial defects (PED). KIO-201 will be administered six (6) times per day while awake for 4 weeks.
- Trial name
- NCT05436288
- Testing
- KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Persistent Corneal Epithelial Defect
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy.
- Trial name
- NCT03687632
- Testing
- ST266
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Persistent Epithelial Defect
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
- Trial name
- NCT00821561
- Testing
- Nexagon®, Nexagon® vehicle
- Volunteers
- 90 people
- Sponsor
- OcuNexus Therapeutics, Inc.